Equities research analysts expect BioScrip Inc (NASDAQ:BIOS) to announce ($0.03) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for BioScrip’s earnings, with estimates ranging from ($0.04) to ($0.01). BioScrip posted earnings per share of ($0.15) in the same quarter last year, which suggests a positive year-over-year growth rate of 80%. The company is expected to report its next quarterly earnings results on Thursday, March 14th.
According to Zacks, analysts expect that BioScrip will report full year earnings of ($0.33) per share for the current financial year, with EPS estimates ranging from ($0.34) to ($0.31). For the next financial year, analysts forecast that the business will report earnings of ($0.18) per share, with EPS estimates ranging from ($0.23) to ($0.14). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow BioScrip.
BioScrip (NASDAQ:BIOS) last issued its earnings results on Tuesday, November 6th. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.02). The firm had revenue of $181.00 million during the quarter, compared to the consensus estimate of $171.35 million. During the same period last year, the firm earned ($0.12) earnings per share. BioScrip’s revenue for the quarter was down 8.9% on a year-over-year basis.
Several large investors have recently added to or reduced their stakes in the stock. Venor Capital Management LP lifted its stake in shares of BioScrip by 0.3% in the third quarter. Venor Capital Management LP now owns 14,475,087 shares of the company’s stock worth $44,873,000 after acquiring an additional 50,000 shares in the last quarter. BlackRock Inc. lifted its stake in shares of BioScrip by 0.4% in the third quarter. BlackRock Inc. now owns 7,616,244 shares of the company’s stock worth $23,610,000 after acquiring an additional 31,899 shares in the last quarter. Vanguard Group Inc lifted its stake in shares of BioScrip by 0.5% in the third quarter. Vanguard Group Inc now owns 5,987,679 shares of the company’s stock worth $18,562,000 after acquiring an additional 27,904 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of BioScrip by 0.5% in the third quarter. Vanguard Group Inc. now owns 5,987,679 shares of the company’s stock worth $18,562,000 after acquiring an additional 27,904 shares in the last quarter. Finally, FMR LLC lifted its stake in shares of BioScrip by 3.3% in the second quarter. FMR LLC now owns 5,593,200 shares of the company’s stock worth $16,388,000 after acquiring an additional 179,700 shares in the last quarter. Institutional investors and hedge funds own 82.09% of the company’s stock.
Shares of NASDAQ BIOS traded up $0.07 on Thursday, hitting $3.76. The company had a trading volume of 336,751 shares, compared to its average volume of 857,600. BioScrip has a 12-month low of $2.31 and a 12-month high of $4.14. The company has a market capitalization of $475.03 million, a price-to-earnings ratio of -8.55 and a beta of 0.61.
BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.
Featured Article: How to Trade Using Analysts Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.